Browse News
Filter News
Found 809,097 articles
-
Despite being hit with a continuing decline in COVID-19 sales and a strong Swiss franc, Roche on Wednesday reported first-quarter sales were up 2% at constant exchange rates.
-
The FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the blood-brain barrier, for the treatment of relapsed or refractory pediatric low-grade glioma.
-
An undisclosed once-daily oral dose of Neurocrine Biosciences’ Takeda-partnered investigational drug significantly reduced symptom severity in adults with major depressive disorder.
-
While Sanofi restructures and parts with employees from U.S. and Belgian sites, a new company in the GLP-1 space emerges from stealth.
-
Policy changes by health insurance companies will likely determine which Humira biosimilars rise to the top.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission
4/24/2024
Nutriband Inc. announced that it has closed the $8.4 million private placement to fund the commercial development program for its lead product, AVERSA™ Fentanyl.
-
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
4/24/2024
Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully closed a Non-Brokered Private Placement offering of units.
-
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
4/24/2024
REGENXBIO Inc. announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.
-
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
4/24/2024
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc., announced that positive results from the Phase 3 oral zoliflodacin trial will be highlighted in an oral presentation given by the Global Antibiotic Research & Development Partnership at the European Society of Clinical Microbiology and Infectious Disease Global Congress taking place April 27-30, 2024, in Barcelona, Spain.
-
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
4/24/2024
Alkermes plc announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1.
-
Meihua International Medical Technologies Co., Ltd. Reports 2023 Financial Year Results
4/24/2024
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, reported its financial results for the fiscal year ended December 31, 2023.
-
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
4/24/2024
RedHill Biopharma Ltd. announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes' U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment.
-
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
4/24/2024
Travere Therapeutics, Inc., and CSL Vifor announced that the European Commission has granted conditional marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day.
-
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
4/24/2024
ASLAN Pharmaceuticals announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease has been accepted for a late breaking poster presentation at the American Thoracic Society International Conference 2024.
-
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
4/24/2024
atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first patient has been dosed in Part 2 of Beckley Psytech’s Phase 2a study, evaluating BPL-003 in patients living with Treatment Resistant Depression.
-
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
4/24/2024
Chemomab Therapeutics Ltd. announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time.
-
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
4/24/2024
First Wave BioPharma, Inc. announced research generated from two previously completed Phase 2 clinical trials of latiglutenase has been published in the special issue "Recent Advances in Gluten-Free Diet and Celiac Disease" in the peer-reviewed scientific journal, Nutrients.
-
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
4/24/2024
United Therapeutics Corporation, announced that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024.
-
LSL Pharma Group Secures $3.8 Million as the Second and Final Tranche of Its Private Placement of Units
4/24/2024
LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, announced the second and final tranche of its private placement financing of Units for $3.8 million representing the second closing of the upsized $7.5 million non-brokered private placement announced on April 11, 2024.